IWF vs XBI
iShares Russell 1000 Growth ETF vs SPDR S&P Biotech ETF
- • IWF has the lower expense ratio at 0.18% vs 0.35% for XBI.
- • IWF pays a higher dividend yield (0.37%).
Side-by-side metrics
| Metric | IWF | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.18% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.37% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $120.29B | $10.92B |
YTD return | -2.54% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.19 | 1.01 |
P/E ratio | 29.18 | — |
Last price | $117.42 | $156.41 |
Inception | — | — |
Issuer | iShares | State Street |
IWF top holdings
| NVDA | NVIDIA Corp | 14.94% |
| AAPL | Apple Inc | 8.45% |
| MSFT | Microsoft Corp | 6.07% |
| GOOGL | Alphabet Inc Class A | 5.10% |
| AVGO | Broadcom Inc | 4.75% |
| GOOG | Alphabet Inc Class C | 4.14% |
| TSLA | Tesla Inc | 3.66% |
| LLY | Eli Lilly and Co | 3.54% |
| META | Meta Platforms Inc Class A | 3.46% |
| MU | Micron Technology Inc | 3.12% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About IWF
IWF (iShares Russell 1000 Growth ETF) is Russell 1000 growth stocks. Managed by iShares, the fund carries $120.3B in assets under management, an expense ratio of 0.18%, a dividend yield of 0.37%. Its largest holding is NVIDIA Corp (NVDA), which represents 14.9% of the portfolio. Real Estate is the fund's largest sector exposure at 0.4%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.